SAG
RARE icon

SageView Advisory Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

SageView Advisory Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-210
Closed -$4.83K – 1992
2025
Q4 		$4.83K Buy
+210
New +$6.91K ﹤0.01% 1980

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

SageView Advisory Group's RARE Position: Q1 2026 in Review

SageView Advisory Group sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 210 shares — an estimated $4.83K sold.

SageView Advisory Group first reported a position in RARE in Q4 2025 and held it in 1 quarter. The position peaked at $4.83K in Q4 2025. 298 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • SageView Advisory Group reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 210 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $4.83K.
  • SageView Advisory Group first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Ultragenyx Pharmaceutical position peaked at $4.83K in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.